Zobrazeno 1 - 10
of 72
pro vyhledávání: ''
Autor:
Russ Wada, Ophelia Yin, Malaz Abutarif, Frank LaCreta, Seiko Endo, Kazutaka Yoshihara, Yuan Xiong, Tushar Garimella
Publikováno v:
Clinical Pharmacology and Therapeutics
Trastuzumab deruxtecan (DS-8201) is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate with a novel enzyme-cleavable linker, a topoisomerase I inhibitor payload, and a drug-to-antibody ratio of ≈ 8. We have characte
Autor:
Norman Stockbridge, Michael Pacanowski, Jielin Sun, T. Beasley, Nita A. Limdi, Jeffry Florian
Publikováno v:
Clin Pharmacol Ther
Chronic kidney disease is a common comorbidity among patients taking direct-acting oral anticoagulants (DOACs). Herein, we evaluate the influence of kidney function on stroke or systemic embolism (SEE), hemorrhage, and composite end points (stroke/SE
Publikováno v:
Clin Pharmacol Ther
Nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease, is increasing in prevalence. NASH-related alterations in hepatic protein expression (e.g., transporters) and in overall physiology may affect drug exposure
Autor:
Yifei Zhang, Jeffrey W. Fisher, Catherine M.T. Sherwin, Daniel Gonzalez, Yaning Wang, Charles J. Ganley, Jian Wang, Lynne Yao, Qunshu Zhang, Mona Khurana, Gilbert J. Burckart
Publikováno v:
Clin Pharmacol Ther
The estimated glomerular filtration rate (eGFR) equations based on serum creatinine (SCR) have been used for pediatric dose adjustment in drug labeling. This study evaluated the performance of those equations in estimating individual clearance of dru
Publikováno v:
Clinical Pharmacology and Therapeutics. 52:24-30
The pharmacokinetic parameters of cefpirome (HR 810) were examined in 22 patients with different degrees of renal impairment. HPLC was used to analyze samples of blood and urine for cefpirome; an enzymatic assay of creatinine in serum and urine was u
Publikováno v:
Clinical Pharmacology and Therapeutics. 51:271-277
Many patients with diabetes who may benefit from treatment with tolrestat, a new aldose reductase inhibitor, will have nephropathy. Therefore the effect of renal dysfunction on the pharmacokinetics of tolrestat was evaluated in eight subjects maintai
Publikováno v:
Clinical pharmacology and therapeutics. 84(2)
Nicotine and its proximate metabolite cotinine are eliminated in part by renal clearance. These compounds are filtered, secreted, and reabsorbed, and the resultant renal clearances are quite variable among individuals and are highly influenced by uri
Publikováno v:
Clinical pharmacology and therapeutics. 83(5)
Alvimopan, a mu-opioid antagonist without anti-analgesic effects, is being developed to manage postoperative ileus. We characterized the population pharmacokinetics of orally administered alvimopan and its primary metabolite in healthy subjects/speci
Publikováno v:
Clinical pharmacology and therapeutics. 57(6)
Objectives The pharmacokinetics of toremifene was investigated in an open study with four parallel groups of 10 subjects each. Subjects with impaired liver function (biopsy-proven liver disease), activated liver function (drug-induced), and impaired
Publikováno v:
Clinical pharmacology and therapeutics. 55(5)
To determine whether erythropoietin alters the renal excretion of a sodium load in humans, we administered either erythropoietin (150 units/kg) or vehicle intravenously in a randomized crossover design to six normal white men on day 4 of a controlled